Adenoid cystic carcinoma is a rare malignant tumor that is well known for its deceptively encouraging 5-year survival rate and its dismal survival rate at longer intervals. Controversy exists as to the benefit of regularly following asymptomaticpatients to lookfor distant metastases because even if one is found, the options for furth er management are limited. When a metastasis is limited to the lung in an asymptomatic patient with no loco regional recurrence, metastasectomy might provide some long-term benefit, although we cannot know for certain. We encountered such a case, and we opted for surgical resection rather than a conservative approach. There isa needfor multicenter trialssothat the management of such patients, be it active or conservative, can be evidence-based.
Introduction
Adenoid cystic carcin om a (ACe) is an aggre ssive epit helial tumor that is well known for its indolent course and ultimately poor prognosis. Whe n it occurs in the head and neck, ACC most commonly arises in the minor salivary glands . ACC accounts for 10% of all salivary neoplasms an d less than 1% of all tumors of the larynx.P Laryngeal ACC usually arises from the subglott ic area near the tracheal junction, and it tends to spread circumferentially before invading intrinsic laryngeal mu scles and cartil age. The thyroid becomes involved via anterior spread through the cricothyroid From mem bra ne, and tracheal invasion occurs via caudal extension of th e tumor.' Hematogenous spread is common in both the early and late courses of ACe. The lung is the most common site of metastasis, as pulmonary metastases have been reported in more than 40% of patients with ACC of the head and neck.v' Once ACC of the head and neck becomes symptomatic or when a visceral extrathoracic metastasis appears, the course of the disease becom es fairly predictable, and patients seldom surv ivefor m ore than 2 years. However,this does not appear to be th e case in asymp tomatic patients when the on ly detectable site of spread is the lung; these pat ients genera llyexper ience a much longer survival.Therefore,the presence of a lun g metastasis in an asymptomatic patient with no local recurrence poses a dilemm a for both the physician and patient regarding the initiation of treatm ent , if any.
Th e literatur e concern ing the appropriate man agement of metastatic laryngeal ACC in an asymp tomatic patient with no local recurrence is limited because of the scarcity of reported cases. In th is article, we discuss the problems posed by such a case at our institution, and we review the evidenc e for and against the use of various interventions.
Case report
A29-year-old woman first presented to the RoyalNational Throat, Nose and Ear Hospital in London in 1988 with an 8-month history of hoarseness and mild shortness of breath. She was found to have a 6-cm tu mor that had arisen in the subglottis, extended dow n the trachea, and infiltrated the cricoid cartilage, the trac heal muscle, the surrounding soft tissue, and the thyroid. She was treated with a total wide-field laryngectomy, total thyroid ectomy,and manubrial resection with postoperativeradiowww.entjournal.com • 969 therapy (4,800 Gy in 22 fractions over 35 days) . She was followed up regularly without further therapy.
Some 15 years later, a routine chest x-ray detected a rounded opacity in the right lower lung over the right heart border and a smaller rounded opacity behind the heart on the left (figure 1). No evidence of local recurrence was noted. Computed tomography (CT) of the chest revealed a well-defined 3.9-cm mass in the apical segment of the right lower lobe and two 0.9-cm subpleural nodules in the left lung-one in the anterior lingula and the other in the anterior segment of the upper lobe (figure 2). The patient was asymptomatic.
The patient was referred to an experienced cardiothoracic surgeon, who decided to proceed to metastasectomy. At thoracotomy, an 8-cm tumor was found occupying the apical and posterior portions ofthe right lower lobe. The tumor did not cross the fissure into the middle or upper lobes, and so a right lower lobectomy was performed. The patient experienced an excellent recovery. Three months later, a left thoracotomy was performed to remove the metastases from the left side. Intraoperatively, multiple secondary nodules were found that had not been previously detected by CT. During this procedure, nodules from the upper lobe, the posteriorly situated segment of the left lower lobe, and the inferior pulmonary ligament were removed.
Two years later, the patient exhibited no evidence of metastatic disease. She continued to be monitored with yearly imaging.
Discussion
Surgical resection. It can be difficult to establish absolute criteria by which to select patients for pulmonary metastasectomy. It has been advocated that conservative excision ofpulmonary metastases should be undertaken when the primary tumor has been controlled and there is no evidence ofextrathoracic metastasis. Other significant considerations are the likelihood ofa complete resection of all pulmonary metastases, the presence or absence of a sufficient cardiopulmonary reserve to accommodate resection, and the lack of a better alternative systemic therapy.Y The lung is the most common site of ACC metastasis, and it is frequently the only site of distant spread. At the time the lung metastases were detected in our patient, she had no evidence of distant spread to any other site.
Long tumor-doubling times have been associated with better long-term survival." The doubling time of lung metastases from an ACC is significantly longer than that of more common solid lung tumor metastases." In a retrospective study, Umeda et al found that the tumor-doubling time of metastatic deposits ranged between 86 and 1,064 days (mean: 393) . 9 Another factor that has been suggested to be correlated with long-term survival is the length of time between the resection of a primary tumor and the development of pulmonary metastases.3,10 Takagi et al studied 8 cases of head and neck ACC and found that the time to metastasis ranged from 13 to 77 months (mean: 31.7).11 In patients with ACC of salivary gland origin, disease-free intervals ranging from 1 month to as long as 19 years have been reported.P-" The disease-free interval in our patient was approximately 15 years.
Liu et al investigated the role of pulmonary metastasectomy in patients with both squamous and glandular head and neck cancers." They found that the 5-year survival rate was 84% among patients who underwent resection of pulmonary metastases from a head and neck primary ACe. However, as was previously mentioned, the course of ACC is such that 5-year survival is not a useful indicator of cure or a predictor of long-term survival. Indeed, in the study by Liu et al, the survival rate declined until no patient was alive at 14 years. Patients who have only one or two pulmonary nodules are believed to experience better outcomes after pulmonary resection, but this is by no means an absolute criterion for identifying good surgical candidates. In fact, Liu et al made the interesting finding that there was no difference in survival between pa tie nts who had a solitary nodul e and those who had multiple lesions.I;
Rendina et al described 6 cases in which pulmonary metastases from laryngeal carcinomas were resected in patients who had no local recurrence or evidence of metastasis to ot her orga ns. IS They con cluded that such patients sho uld be con sidered for surgica l resection regar dless of cancer stage, the numbe r of lun g Volume 88 , Number 6 metastases, or the disease-free interval as long as the patient is in good health.
In a recent review of lun g m etastasectomy for ACC at a single inst itution, Locati et al retrospectively analyzed data from 20 patients with ACC of salivary gland or igin. " The surgical results were classified according to the extent of residual carci noma; the three categories of residual disease were none (RO), microscopic (Rl ), and macroscopic (R2). Eleven patients achieved RO stat us, and 9 were classified as R2. Of the 11 diseasefree patient s, 4 were alive 4 years after surgery witho ut evidence of disease. Of th e 9 pati ents with macroscopi c residuum, 4 were alive after 4 years, including 2 who had experienced a local recurrence at the primary tumor site. Median surviva l after m etastasectomy in the RO and R2 gro ups was 78 and 52 m on ths, respectively. Subgroup analysisrevealed that a disease-free interval of more tha n 36 mo nt hs and a low tu m or burden defined a gro up of patie nts who had a bett er prognosis after metastasectomy.The aut hors pointed out th at itwas not pos sible to determine whether th ese two associations translate int o any long-term survival benefit. In addition , comp lete clearance of th e lung is very imp ort ant if any benefit is to be conferre d.
Th e most recent retrospective study at a single center identified 9 patients with pulmo nary metas tases from ACC of the head and neck with no locoregional recurrence who were treate d with metastasectomy." Criteria for surgery included (1) th e absence of any other site of tumor recurre nce, (2) the possibility that a com plete resection of th e lun g nodules could be accomplished, and (3) a sufficient pulmon ary fun ction al reserve to accom mo date the plann ed lung pa ren chymal resection . Mean survival in this group was 72 months, compared with a mean survival of 62 months in a group of 11 patients with lung metastases who did not undergo surgery. However, 7 of those 11 patients had multiple sites of distant metastasis, so a fair comparison is difficult to make.
Finally,because several years m ay pass between resection of a pr imary head and neckACC and the detection of a pulmonary metastasis, th e poss ibility of a new pr imary non-ACC tumor must be considered . Fine-needle aspiration biopsy has been shown to be useful for the pathologic confirmation of a pulmonary metastas is in a patie nt with previo usly treated ACC. I S Chemotherapy. Cisplatin therapy has been shown to be of benefit in tu mor types oflow growth fraction. Schramm et al repo rted favorable subjective respo nses and objective tumo r regression with cisplatin chem owww.entjournal.com • 97 1 therapy in patients with ACC metastatic to the lung." Budd and Groppe reported a complete and sustained response to the combination of 5-fluorouracil, doxorubicin, and mitomycin C-collectively known as FAM-in a patient withACC ofthe parotid gland widely metastatic to the pleura, pulmonary parenchyma, skin, and bone." Petursson found that FAM therapy was associated with a regression of pulmonary nodules in a patient with metastatic ACC of the esophagus." The combination of cyclophosphamide, doxorubicin, and cisplatin has shown some activity in patients with metastatic ACC of the salivary glands."
The use of cisplatin-based chemotherapy and cisplatin-based combination therapy has also been investigated for advanced ACC of the head and neck. In a study by de Haan et al, 10 patients received cisplatin alone (50 to 120 mg/rrf intravenously every 4 weeks) and 9 patients received a combination of cisplatin (20 mg/rrf IV on days 1 through 5), doxorubicin (50 mg/m-on day 1), and bleomycin (30 mg IV on days 1 through 5). 23 The authors concluded that despite some response (which occurred only in the combination group), the overall impact of therapy on survival in the responders was unclear. The median progression-free survival was 36 months (range: 7 to 77), and the median overall survival was 81 months (range: 14 to 216). One of the patients in the combination group was a 73-year-old man withACC of the larynx metastatic to the lung who had also been treated with radiotherapy. He experienced a complete remission after two cycles of chemotherapy.
Epirubicin has been shown to be of some use in patients with rapidly progressive and/or symptomatic disease." Phase II trials have also revealed that mitoxantrone has modest activity in recurrent and metastatic ACC of the head and neck." Finally, a recent phase II study of gemcitabine in recurrent and/or metastatic ACC of the head and neck found that this agent was not an active drug in ACe.26 C-kit expression. High levels of c-kit (CD 117) expression have been identified in 90% of salivary gland ACCsY The pharmacologic agent imatinib, which was designed to treat chronic myelogenous leukemia by inhibiting BCR-ABL tyrosine kinase, has recently been shown to target c-kit as well. Cell culture studies have shown that imatinib inhibits ACC growth and that there is a synergistic interaction between imatinib and cisplatin."
The results of some early studies of imatinib were promising.Alcedo et al reported 2 cases of ACC treated with imatinib." One patient experienced a significant 972 • www.entjournal.com regression of recurrent disease, which allowed for a successful salvage resection. The other patient, who had locally advanced disease, also responded to treatment.
On the other hand, less promising results were reported by Hotte et aI, who conducted a phase II trial of oral imatinib for the treatment of ACC of the salivary gland. " Of 16 patients with unresectable or metastatic ACC, the best response was only a stabilization of disease, which occurred in 9 patients. Disease in the other 6 patients continued to progress after two cycles of chemotherapy.
Another recent phase II study of 14 patients with locally advanced or metastatic ACC of the head and neck who were treated with oral imatinib found no objective responses."
Further studies ofchemotherapy would be helpful, but the rarity of the tumor makes them difficult to conduct. Nevertheless, research into targeted therapy may be a more useful exercise than research into modifications of current regimens that are already known to be of limited use.
In conclusion, it is importantto remember that 5-year survival is not a good indicator of long-term survival for patients with ACe. Patients can develop a recurrence or distant metastasis 10 or 20 years after treatment and ultimately die from it. Lung metastases of ACC are usually asymptomatic and are generally picked up incidentally on routine chest radiography. Indeed, even patients with widespread pulmonary metastases may remain asymptomatic until very late in the course of their disease. Thus, significant lung involvement does not indicate an imminent deterioration of function.
The definitive role of chemotherapy in the management of ACC has yet to be established. Given the long natural history and indolent course ofACC, it is difficult to conclude that any particular chemotherapeutic regimen can slow its progression. The fact that metastatic lesions remain static cannot be used as evidence of drug efficacy.
Despite the ultimately poor long-term prognosis for patients with ACC, there may be instances when aggressive treatment of asymptomatic metastatic disease isolated to the lung should be considered. Until sufficient long-term follow-up data become available from tertiary care centers where ACC lung metastases are treated, we recommend that lung metastasectomy be considered for carefully selected cases of ACC metastasis restricted to the lung. However, a m ulticen tel'trial would be required to establish whether surgery in such patients confers a survival benefit. 
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